IHC

PD-L1 (22C3)(FDA)

Identifies PD-L1 expression on tumor cells and tumor-associated immune cells. The 22C3 clone is FDA-approved as a companion diagnostic for selecting patients who may benefit from anti–PD-1/PD-L1 immunotherapies, including pembrolizumab. It is used across multiple tumor types, including non–small cell lung carcinoma, head and neck squamous cell carcinoma, gastric/GEJ adenocarcinoma, cervical cancer, and urothelial carcinoma.

Full Description

Identifies PD-L1 expression on tumor cells and tumor-associated immune cells. The 22C3 clone is FDA-approved as a companion diagnostic for selecting patients who may benefit from anti–PD-1/PD-L1 immunotherapies, including pembrolizumab. It is used across multiple tumor types, including non–small cell lung carcinoma, head and neck squamous cell carcinoma, gastric/GEJ adenocarcinoma, cervical cancer, and urothelial carcinoma.

Methodology

IHC

Specimen Requirements

Tissue Block: Formalin-fixed, paraffin-embedded (FFPE) tumor block preferred. Unstained Slides: Recommended 2 charged slides per stain requested (minimum of 1 slide per stain), baked or unbaked. Fixation: Tissue must be fixed in 10% neutral buffered formalin for 6–72 hours.

Storage and Transportation

Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.

Turnaround Time

88342x1 or 88341x1

CPT Codes

24 Hrs